NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $16.97 +1.57 (+10.19%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$17.10 +0.13 (+0.77%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neurogene Stock (NASDAQ:NGNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neurogene alerts:Sign Up Key Stats Today's Range$15.54▼$17.4550-Day Range$7.34▼$17.7852-Week Range$6.88▼$74.49Volume199,880 shsAverage Volume231,525 shsMarket Capitalization$242.03 millionP/E RatioN/ADividend YieldN/APrice Target$47.20Consensus RatingBuy Company OverviewNeurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Read More… Neurogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreNGNE MarketRank™: Neurogene scored higher than 39% of companies evaluated by MarketBeat, and ranked 616th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has only been the subject of 3 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurogene is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurogene is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.36% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 17.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.36% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 17.21%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.86 News SentimentNeurogene has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Neurogene this week, compared to 3 articles on an average week.Search Interest1 people have searched for NGNE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,247.00 in company stock.Percentage Held by InsidersOnly 9.92% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address NGNE Stock News HeadlinesNeurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual MeetingApril 28, 2025 | businesswire.comNeurogene price target lowered to $16 from $45 at BMO CapitalApril 14, 2025 | markets.businessinsider.comDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 5, 2025 | Weiss Ratings (Ad)Neurogene modifie son accord et émet des bons de souscriptionApril 14, 2025 | fr.investing.comBMO réduit l’objectif de cours de Neurogene à 16$ contre 45$, maintient SurperformanceApril 14, 2025 | fr.investing.comL’action NGNE touche son plus bas niveau sur 52 semaines à 8,35$April 7, 2025 | fr.investing.comNeurogene announces peer-reviewed publication of EXACT transgene technologyApril 3, 2025 | markets.businessinsider.comNeurogene annonce des progrès dans sa technologie de régulation de thérapie géniqueApril 2, 2025 | fr.investing.comSee More Headlines NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $22.86 at the beginning of 2025. Since then, NGNE shares have decreased by 25.8% and is now trading at $16.97. View the best growth stocks for 2025 here. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) released its quarterly earnings results on Monday, March, 24th. The company reported ($0.99) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05. The business earned $0.93 million during the quarter. Who are Neurogene's major shareholders? Top institutional investors of Neurogene include Bank of New York Mellon Corp (0.16%) and GAMMA Investing LLC (0.03%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn and Christine Mikail Cvijic. View institutional ownership trends. How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON). Company Calendar Last Earnings3/24/2025Today5/04/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year FoundedN/APrice Target and Rating Average Stock Price Target$47.20 High Stock Price Target$72.00 Low Stock Price Target$16.00 Potential Upside/Downside+178.1%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,320,000.00 Net MarginsN/A Pretax Margin-5,756.43% Return on Equity-32.81% Return on Assets-27.96% Debt Debt-to-Equity RatioN/A Current Ratio9.09 Quick Ratio9.09 Sales & Book Value Annual Sales$925,000.00 Price / Sales261.65 Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book1.17Miscellaneous Outstanding Shares14,262,000Free Float13,381,000Market Cap$242.03 million OptionableOptionable Beta1.46 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NGNE) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.